These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

334 related items for PubMed ID: 11209044

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Vascular and haematopoietic stem cells: novel targets for anti-angiogenesis therapy?
    Rafii S, Lyden D, Benezra R, Hattori K, Heissig B.
    Nat Rev Cancer; 2002 Nov; 2(11):826-35. PubMed ID: 12415253
    [No Abstract] [Full Text] [Related]

  • 3. Tumoral vascularity as a prognostic factor in cancer.
    Weidner N, Folkman J.
    Important Adv Oncol; 1996 Nov; ():167-90. PubMed ID: 8791135
    [No Abstract] [Full Text] [Related]

  • 4. Angiogenesis in multiple myeloma.
    Sezer O, Niemöller K, Jakob C, Heider U.
    Leuk Res; 2002 Jul; 26(7):701-2. PubMed ID: 12008091
    [No Abstract] [Full Text] [Related]

  • 5. Cancer: Limitations of therapies exposed.
    Casanovas O.
    Nature; 2012 Apr 04; 484(7392):44-6. PubMed ID: 22481354
    [No Abstract] [Full Text] [Related]

  • 6. [Significance of vascular endothelial growth factor--VEGF--in tumor angiogenesis. Therapeutic possibilities in solid tumors].
    Werther K, Nielsen HJ.
    Ugeskr Laeger; 2000 Sep 11; 162(37):4916-20. PubMed ID: 11002739
    [No Abstract] [Full Text] [Related]

  • 7. Vascular endothelial growth factor as a target for antiangiogenic therapy.
    Gordon MS.
    J Clin Oncol; 2000 Nov 01; 18(21 Suppl):45S-6S. PubMed ID: 11060326
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Anticancer therapy with angiogenesis inhibitors.
    Ghilardi C, Bani MR, Giavazzi R.
    Tumori; 2001 Nov 01; 87(6):S14-6. PubMed ID: 11989610
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Use of tumor-activated hepatic stellate cell as a target for the preclinical testing of anti-angiogenic drugs against hepatic tumor development.
    Olaso E, Vidal-Vanaclocha F.
    Methods Mol Med; 2003 Nov 01; 85():79-86. PubMed ID: 12710199
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Angiogenesis and angiogenesis inhibitors in cancer.
    Giavazzi R, Taraboletti G.
    Forum (Genova); 1999 Nov 01; 9(3):261-72. PubMed ID: 10504172
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Vascular endothelial growth factor is an in vivo survival factor for tumor endothelium in a murine model of colorectal carcinoma liver metastases.
    Bruns CJ, Liu W, Davis DW, Shaheen RM, McConkey DJ, Wilson MR, Bucana CD, Hicklin DJ, Ellis LM.
    Cancer; 2000 Aug 01; 89(3):488-99. PubMed ID: 10931447
    [Abstract] [Full Text] [Related]

  • 19. Circulating endothelial cells as a novel marker of angiogenesis.
    Mancuso P, Calleri A, Cassi C, Gobbi A, Capillo M, Pruneri G, Martinelli G, Bertolini F.
    Adv Exp Med Biol; 2003 Aug 01; 522():83-97. PubMed ID: 12674213
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.